MBX Biosciences is a preclinical-stage biotech company committed to creating therapies to treat rare endocrine diseases where there is inadequate treatment available.
MBX’s leadership team has collaborated successfully over several decades to discover, develop and commercialize first-in-class endocrine therapeutics. A distinguishing strength of MBX is world-class proprietary peptide drug discovery.
Kent Hawryluk, MS, MBAPresident & CEO
Kent Hawryluk has nearly 20 years’ experience as a life sciences entrepreneur, leader and investor. Mr. Hawryluk is President & CEO and one of our co-founders.
Mr. Hawryluk was a Co-founder and Chief Business Officer of Avidity Biosciences, a genetic medicines company, from January 2013 to December 2019. Under his leadership, Avidity raised $130 million in equity financings and initiated a significant strategic partnership with Eli Lilly. Previously, he served as Co-founder and CEO of MB2, a clinical-stage company focused on diabetes and obesity, from May 2014 to March 2016. MB2 was acquired by Novo Nordisk in October 2015. Prior to MB2 and Avidity, Mr. Hawryluk co-founded Marcadia Biotech and served as its Chief Business Officer and Vice President, Business Development from January 2006 to April 2011. Marcadia, a pioneer in peptide multi-agonists of incretin receptors, was acquired by Roche in December 2010. Mr. Hawryluk served as a director of Gemphire Therapeutics, a public clinical-stage cardiovascular drug company, from February 2015 to February 2019. He has served as partner of Twilight Venture Partners, a private seed- and early-stage life science venture capital fund, since January 2003. Mr. Hawryluk holds a BA from Princeton University, an MBA from Kellogg School of Management at Northwestern University, and an MS, Biology from Purdue University.
Tim KnickerbockerChief Operating Officer
Timothy Knickerbocker is an Indiana native and Purdue University alumnus, seasoned by professional employment in the Midwest and California. He has served in leadership roles in project management and operations pertaining to the life sciences. Mr. Knickerbocker is COO and one of our co-founders.
Prior to his time at MBX, Mr. Knickerbocker successfully led teams in the building of some of the most technically advanced healthcare facilities in the country. He is currently complementing his operational duties at MBX with an Executive MBA education from the Anderson School of Management at UCLA.
Richard DiMarchi, PhDChief Scientific Officer
Richard DiMarchi, PhD, is one of the world’s leading peptide chemists, and has made key contributions to the biotech industry for 40 years as an academic, an inventor, an entrepreneur and a scientific executive.
Dr. DiMarchi is currently Distinguished Professor of Biochemistry and Gill Chair in Biomolecular Sciences at Indiana University and separately serves as Vice President of Research at Novo Nordisk Research Labs in metabolic diseases. He is a co-founder and director of Assembly Pharmaceuticals, a clinical-stage public biotech company focused on treatments for hepatitis B and microbiome-associated disorders. Previously, Dr. DiMarchi was a co-founder and director of biotechnology companies Ambrx and Marcadia Biotech; a founder and director of Calibrium; and a partner of Twilight Ventures. He also served as a director of Ionis and Millennium BioTherapeutics. At Eli Lilly, Dr. DiMarchi served as global leader of biotechnology and designed the first insulin analog, Humalog®. He also contributed to the commercial development of major pharmaceutical products such as Forteo®, Glucagon®, Evista®, Humatrope® and Humulin®. He is an inductee of the National Inventors Hall of Fame and the National Academy of Medicine. Dr. DiMarchi received a BS in Chemistry with honors from Florida Atlantic University and a PhD in Biochemistry from Indiana University. He completed a postdoctoral fellowship at The Rockefeller University with Bruce Merrifield.
Lisa Redman, CPAVice President, Finance
Lisa J. Redman has more than 25 years of finance and accounting experience. Ms. Redman is our Vice President, Finance.
Previously, Ms. Redman was head of finance for MB2 during its purchase of Marcadia Biotech and its acquisition by Novo Nordisk. She has served in key finance roles in numerous biotechnology companies including Crinetics Pharmaceuticals and Auspex Pharmaceuticals where she was integrally involved with their IPO preparations. Further, Ms. Redman also helped companies with SEC reporting, Sarbanes-Oxley implementations and grant compliances.
Ms. Redman was a CFO of a publicly held technology company and a controller of several venture-backed companies in a variety of industries including medical devices, food distribution and mortgage banking. She began her career as an auditor for Coopers & Lybrand (now PWC) where she served both public and private companies. Ms. Redman holds a bachelor’s degree in Business Administration from San Diego State University. She is a Certified Public Accountant in the State of California (on inactive status).
Greg Davis, PhDVice President, Product Development
Greg Davis, PhD, has nearly 35 years’ experience in drug development in biotech and pharma. Dr. Davis is our Vice President, Product Development.
Dr. Davis has served as Chairman of the Board of Inotiv, a publicly-traded clinical research organization, since June 2017. He served as Vice President of CMC, Regulatory and Quality at Calibrium, a biotech company developing novel biotherapeutics for the treatment of diabetes, from May 2014 to December 2015. The company was sold to Novo Nordisk in October 2015. From 1992 to 2012, Dr. Davis held various leadership positions at Eli Lilly in Biotechnology Product Development, Global Regulatory Affairs, Global Brand Teams, and Quality. When he retired from Eli Lilly in December of 2012, he was Executive Director and Senior Principal Fellow in Global Regulatory Affairs. Dr. Davis has held numerous leadership positions within the Pharmaceutical Research and Manufacturers Association (PhRMA), the United States Pharmacopeia (USP), and the Biotechnology Industry Organization (BIO). He also served for five years as the PhRMA liaison to the International Conference on Harmonization (ICH) for Q5/Q6 Biotechnology topics. Dr. Davis received his bachelor’s degree from Southeast Missouri State University and his PhD in Analytical Chemistry from Purdue University.
Skip Vignati, MD, MSSenior Medical Consultant
Dr. Louis “Skip” Vignati, Senior Medical Consultant, is a board-certified endocrinologist with broad clinical and drug discovery experience spanning 40 years. Dr. Vignati served as Vice President, Medical Affairs at Calibrium, a biotech company developing novel biotherapeutics for the treatment of diabetes, from June 2014 until Calibrium was acquired by Novo Nordisk in December 2015. Previously, he was Vice President, Medical at Marcadia Biotech, a pioneer in peptide multi-agonists of incretin receptors, from September 2006 to April 2011. Marcadia was acquired by Roche in December 2010.
He received an undergraduate degree from the University of Pennsylvania, a graduate degree in organic chemistry from American University and a medical degree from Thomas Jefferson University. He completed his house staff training at the University of Vermont and Endocrine Fellowship at the Peter Bent Brigham Hospital and the Elliot P. Joslin Research Laboratory in Boston, Massachusetts. He served as an officer in the USPHS in the Toxicology Branch of the National Institute of Health for Occupational Safety and Health.
Following his fellowship, Dr. Vignati was senior physician at the Joslin Diabetes Center in Boston, Massachusetts. In 1990 he joined Eli Lilly and Company and served as the Medical Director for development of early phase endocrine compounds. At Lilly he participated in the global development of new therapies for the treatment of diabetes and its complications and obesity including Humalog®, Recombinant Glucagon®, and Forteo® among others. Dr. Vignati has been a principal investigator for numerous clinical trials and co-investigator for the DCCT (Diabetes Control and Complications Trial).
Kristin EatonSenior Intellectual Property Consultant
Kristin Eaton has 24 years’ cumulative experience in scientific research and intellectual property development.
Upon graduating from the University of Chicago with a BA in biology, Kristin conducted research at the University of Chicago Hospital’s Department of Neurology. Following this she worked in stem cell transplantation research at the University of Minnesota prior to and throughout the establishment of the UMN Stem Cell Institute. King & Spalding’s biotechnology IP group recruited Kristin for her unique skill set and while employed in their Atlanta office she passed the patent bar and spent years learning the details of patent prosecution, licensing, and investor due diligence before bringing those skills to bear in a stem cell focused biotechnology company in Massachusetts. Kristin moved to California where she has served as in-house IP director and strategist for a number of biotechnology companies in San Diego including Ambrx and Vividion. She works to combine her experiences with cutting-edge science and its interplay with politics and policy to pursue broad and innovative patent protection.